Repligen Corporation $RGEN Stake Lessened by Legal & General Group Plc

Legal & General Group Plc lessened its holdings in Repligen Corporation (NASDAQ:RGEN) by 6.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,803 shares of the biotechnology company’s stock after selling 4,995 shares during the period. Legal & General Group Plc owned about 0.14% of Repligen worth $12,913,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of RGEN. Hantz Financial Services Inc. lifted its stake in Repligen by 120.6% in the 4th quarter. Hantz Financial Services Inc. now owns 1,293 shares of the biotechnology company’s stock worth $212,000 after acquiring an additional 707 shares in the last quarter. Swedbank AB acquired a new position in shares of Repligen in the 4th quarter valued at about $4,146,000. Coldstream Capital Management Inc. lifted its position in shares of Repligen by 5.3% in the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 101 shares in the last quarter. Lisanti Capital Growth LLC acquired a new stake in shares of Repligen during the fourth quarter worth approximately $3,189,000. Finally, Americana Partners LLC acquired a new stake in shares of Repligen during the fourth quarter worth approximately $224,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on RGEN. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the company a “buy” rating in a research note on Friday, April 17th. KeyCorp restated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. HC Wainwright upped their price target on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Wells Fargo & Company reduced their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Stock Performance

RGEN stock opened at $121.13 on Wednesday. The firm has a 50 day moving average of $118.05 and a two-hundred day moving average of $139.53. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77. The company has a market capitalization of $6.83 billion, a price-to-earnings ratio of 134.59, a P/E/G ratio of 2.37 and a beta of 1.09. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.26 million for the quarter, compared to the consensus estimate of $192.05 million. During the same quarter last year, the firm earned $0.39 EPS. Repligen’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities analysts anticipate that Repligen Corporation will post 1.99 EPS for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.